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Poster Session I S283Multiple viruses have been associated with HC, such as BK polyoma
virus (BKV), CMV, and Adenovirus.
Methods:Medical records of 30 pediatric pts who had undergone
allogeneic or autologous HCT at our center between March of
2007 and April of 2010 have been reviewed. Urine of all patients
was sent for quantitative BKV by PCR. BKV positive was consid-
ered as a load of $ 10E6 copies/ml. CMV was monitored quan-
titatively by PCR. Categorical tables were analyzed using
Pearson’s chi-square test and the Cochran-Mantel-Haenszel test.
Tabular and graphical descriptive survival analyses were per-
formed using cumulative incidence methods accounting for com-
peting risks.
Results:Median age at transplant was 12.3 yrs. Nineteen pts had al-
ternative donor HCT: 13 from a matched unrelated donor, 4 from
double cord blood units (CBU) and 2 from a single CBU. Ten
HCT were from matched related donors (MRD), including 1 with
MRD CBU. One pt had an autologous transplant. All pts had re-
ceived a full myeloablative conditioning therapy. Acute GVHD oc-
curred in 28 pts (96.5%); all were treated with methylprednisolone at
a median dose of 60mg daily. Out of 30 patients 10 (33.3%) patients
had HC at a median of 37 days post HCT (range 24 to 73 days). Five
(50%) had grade II HC, two pts (20%) hadmoderate grade III, and 3
(30%) had severe, grade IVHC.HCoccurred in 2 of 12 (17%) BKV-
pts compared with 8 of 18 (44%) BKV+ pts. (p 5 0.11). One of 10
CMV-, BKV- pts (10%) pts had HC; compared to 5 of 15 (33%)
of CMV+, BKV+ pts. (p 5 0.18). The occurrence of severe HC
was correlated with advanced disease state but not with higher ste-
roid doses.
Conclusion: BKV may play a role in HCT. A prospective study is
needed to better identify the role of BKV and CMV in the develop-
ment of HC.357
MEETING THE CHALLENGE: DEVELOPING A MODEL TO CARE FOR AN
ADOLESCENT PATIENT WITH LEUKEMIA AND SEVERE AUTISM
Bain,M.E.,Martin, P.L., Kojis, S., Trout, S.B., Kurtzberg, J. DukeUni-
verstiy Medical Center, Durham, NC; Duke University Medical Center,
Durham, NC; Duke University Medical Center, Durham, NC; Duke
University Medical Center, Durham, NC; Duke University Medical Cen-
ter, Durham, NC
As a Certified Child Life Specialist (CCLS) for the Duke Pediatric
Blood and Marrow Transplant program, one has to be prepared to
provide specialized services to all children. A CCLS has been trained
to incorporate age, diagnosis, developmental level and special needs
in the assessment of each patient. When a teenage girl with second-
ary leukemia and severe autismwas referred for a bonemarrow trans-
plant, all skills were put to the test. As a team, we worked proactively
to ensure a smooth and safe transition from her home hospital to our
transplant facility.
Our initial challenge was to anticipate the needs of this patient be-
fore we had a chance to meet her. A picture of the CCLS was taken
(labeled ‘‘a safe friend’’) and sent to the patient to begin building
a rapport. The CCLS, social worker and nurse coordinator corre-
sponded regularly with the patient’s caregiver before their arrival
to Durham. This dialogue provided our team with information
that helped form her detailed plan of care, and served as a base to
build a trusting relationship.
After learning about the patient’s communication style, photo-
graphs were taken of doctors, nurses, buildings, exam rooms, patient
room, hallway and waiting area, elevators, procedures, medical in-
struments - even mouth care brushes. The pictures were printed
and labeled with detailed descriptions using the five senses, then
mailed to the patient and family. Our goal was to prepare the patient
for a new care team and medical environment.
Our second challenge was to ensure a safe, trusting, and comfort-
able inpatient stay. Because disruptions to routine would often lead
to negative behavior, we provided a structured schedule, consistent
caregivers, and a plan designed to help the patient cope with unex-
pected events. The CCLSworked closely with the staff, psychosocial
team, and quality of life team educating them on the necessity to give
extra preparation time before transitions and/or procedures to allow
for successful cooperation from the patient. In addition, the patientresponded well to incentives (particularly food) to encourage coop-
eration for necessary daily activities.
This experience has provided our transplant team with a deeper
understanding of how to best serve these patients. The knowledge
gained helped us create a model to implement for future transplant
patients we encounter who fall within the autism spectrum.358
MULTIDISCIPLINARY CARE ON AN IN-PATIENT PEDIATRIC BLOOD AND
MARROW TRANSPLANT UNIT THAT DOES NOT INCLUDE RESIDENT PHY-
SICIANS
Kinsella, T.A., Jacobs, J.A., McLean, S.L., Turner, K., Tarin, R.,
Paff, Z.N., Wallace, G., Longhorn, E., Pesok, A., Eckstein, O.,
Baker, A.L., Berger, S., Bessler, L., Davies, S. Cincinnati Children’s
Hospital, Cincinnati, OH
The care of complex pediatric blood and marrow transplant
(BMT) patients requires numerous skilled and complimentary inter-
disciplinary caregivers. Changes in resident hours have altered the
balance of care givers on our team, which has not included residents
for the last five years. Primary bedside care is given by a team of col-
laborative advanced practive nurses (APN), hospitalists and fellows
seven days a week. Additional team members include in-patient
care managers (coordinators), pharmacists, dieticians, chaplains
and social workers. This team covers all aspects of care including
physical, educational, spiritual, cultural and psychosocial needs.
An attending physician oversees the daily intricate planning that is
carried out by the multidisciplinary team, and daily rounds are
conducted at the bedside with parents participating. Each child has
a primary care provider, either an APN, hospitalist or fellow. Presen-
tation of the child on rounds, order writing, lab interpretation, phys-
ical assessments and initiation of the care of the patient are
consistently managed by the primary care provider. Overnight care
is provided by a hospitalist who sleeps in house and works eight con-
secutive nights, providing continuity of care.
This structure, with limited contribution from rotating physicians
(only the fellows are on a ‘‘rotation’’), provides consistent care pro-
viders who are familiar with a patient’s long hospital course and
unit routines. This also provides a familiar face to families and pa-
tients who can often be readmitted.
The nurse care manager facilitates coordination of services such as
discharge planning, home care teaching, ordering home therapies
and supplies, scheduling and coordinating appointments of other
disciplines. The nurse care managers are also the primary educators
of BMT information to our families. The structure of our unit allows
for consistency, continuity of care and can be described as a solid
workforce and a comfort to those families undergoing BMT.359
VORICONAZOLE AS PRIMARY ANTIFUNGAL PROPHYLAXIS IN RECIPI-
ENTS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FROM ALTERNATIVE DONORS
Cozzi, J., Basso, A., Lein, J., Saslavsky, J., Saslavsky, M., Pilli, V.
CETRAMOR BMT-Unit, Rosario, Santa Fe, Argentina
Background: Invasive Aspergillosis (IA) has been the leading cause
of death from fungal infections in patients undergoing allogeneic
Haematopoietic Stem Cell Transplantation (HSCT), particularly
from donors other than HLA-identical siblings.Given the high mor-
tality rate associated with IA and our inability to reliably diagnose ac-
tive cases, prophylactic therapy with Voriconazole (VOR) a triazole
with broad-spectrum antifungal activity against several molds, in-
cluding Aspergillus, was instituted as Primary Antifungal Prophy-
laxis (PAF-Px) in this high-risk group of patients.
Methods: from 02/09 to 02/10 nine patients(p) who underwent al-
ternative donor allogeneic HSCT and received VOR as PAF-Px
were studied.The patients received VOR 400 mg PO BID x 1 day,
then 200 mg PO BID.VOR was started the day of HSCT and
planned for 100 days.After day +100 VOR was continued in patients
requering corticosteroids for therapy of graft-versus-host-disease
(GVHD). Age,median(range)30(17-54)years. Male sex: 8 p
S284 Poster Session I(88,8%). Underlying diseases CML(1 p), CMML(1 p), AML(2 p),
ALL(3 p), SAA(2 p). Disease state at time of transplant: Refractory
disease: 7 p (77,7%). Conditioning Regimen: Reduced intensity: 6
p (66,6%). ATG(5 p)/CAMPATH-1H(1 p):6 p (66,6%). Donors
Matched Unrelated: 4 p, Mismatched Unrelated: 3 p, Mismatched
Related: 2 p. Graft source: peripheral blood stem cells: 9 p (100%).
Acute GVHD II-IV: 5 p(55,5%) requiring high-doses corticoste-
roids. CMV reactivation: 5 p (55,5%). Pandemic Influenza A
(H1N1) Infection: 1 p (11,1%). All patients had serum Galacto-
mannan(GM) assayed twice weekly.
Results:Median time on prophylaxis was 85(range14-241)days. GM
was positive(+) in three patients (33,3%) at onset PAF-Px VOR.
Breakthrough Invasive Fungal Infections: Candidemia caused by
Candida Glabrata (1 p) (Susceptible to fluconazole and VOR) and
probable IA(EORTC/MSG criteria) (1 p GM + at baseline): 2 p
(22,2%).None of these p died of Invasive Fungal Infection. VOR
therapywasnot discontinued in anypatient becauseof adverse effects.
Seven patients died during the follow up. Cause of death: Relapse:3
p,GVHD:2 p,VOD:1 p,Disseminated Adenovirus infection:1 p.
Conclusion: PAF-Px with VOR was an effective and well tolerated
regimen for Invasive Fungal Infections prevention in this high-risk
patient population studied.CRA – DATA MANAGEMENT
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TWO YEAR EVALUATION OF EVENT REPORTING SYSTEM FOR THE CELL
THERAPY PROCESSING FACILITY
Merchant, M.1, Kletzel, M.1,2, Shook, T.1, Villa, M.1, Meagher, R.1,
Gordon, L.1 1NorthwesternMemorial Hospital & Feinberg School ofMed-
icine, Chicago, IL; 2Children’s Memorial Hospital & Robert H Lurie
Comprehensive Cancer Center, Chicago, IL
Background: The Cell Therapy Processing Facility (CTPF) at
Northwestern Memorial Hospital devised and implemented a new
Event Reporting System (ERS) in September 2008, to capture all
events occurring in theCTPF, so as to improve the quality, efficiency
and safety of the laboratory, its patient, product and personnel.
Events were classified according to their severity from Class I to VI.
Event Classification: I HCT/P Deviation; II SOP Deviation; III
Planned Deviation; IV Equipment/Supply related; V Complaint;
VI Other.
Objective:The reason behind implementing a new ERSwas to clas-
sify events in proper perspective so that we could document the ex-
tent of errors in the CTPF and to further offer solutions to prevent
them from recurring.
Method: Events were recorded for the fiscal year from October
through September. Events between October 2007 and September
2008 were re-classified according to the new system (2008). Events
were recorded against the number of transplants performed, for pur-
pose of comparison. The ERS uses single page reporting with check
boxes for ease in use. It is open to all employees and to all participat-
ing program personnel; and is non-biased and non-discriminatory.
All events, however minor, were encouraged to be reported.
Result:
Table 1.
2008 2009 2010No of Events:1
5
2(
(
(2
5
1n5 69 n5 188 n5 163Class I 2 (3%) 7 (4%) 2 (1%)
Class II 11 ( 6%) 50 27%) 37 ( 3%)
Class III 40 ( 8%) 91 48%) 90 ( 5%)
Class IV 14 ( 0%) 30 16%) 21 ( 3%)
Class V 0 3 (2%) 0
Class VI 2 (3%) 7 (4%) 13 (8%)
No of Transplants 344 401 415
Events Over Transplants 20.1% 46.9% 39.3%
Class I & II Events Over Transplants 3.8% 14.2% 9.4%
Class III Events Over Transplants 11.6% 22.7% 21.7%
Class IV to VI Events Over Transplants 4.7% 10% 8.2%Discussion: We observed that prior to the implementation of the
ERS, many events went undocumented, especially those related to
infectious disease markers, product labeling and those related to
cell processing. Events related to HCT/P or SOP deviation (Class
I & II) are very concerning to any laboratory. The ERS detected
that in 2009, these were at 14.2%, up from 3.8% in 2008.We under-
took an overhaul and revision of our SOP with the current accredit-
ing and regulatory guidelines in mind. Policies were discussed before
and during their writing, training and implementation. Policies are
now sufficiently detailed to cover many possible event scenarios.
The SOP is secured from inadvertent altering or tampering, and is
easy to access and readily available to technicians on the workbench.
Training, retraining and competency issues have been sorted out.
This, we believe has helped us lower the occurence of these events
by 5% in 2010.
Conclusion: Implementing a new ERS has made us aware of the
scope of events in the CTPF and helped us in identifying the key rea-
son behind the events; thus leading to a decline in their number over
two years and especially, a decline in the severity of Class I & II
errors.361
EXPERIENCES FROM TRAINING A DATA MANAGER AT A NEW STEM CELL
TRANSPLANT CENTER
Roepstorff, C., Petersen, H., Larsen, H.B. Rigshospitalet, Finsencentret,
Copenhagen, Denmark
Introduction: Previously there was only one allogeneic trans-
plant centre in Denmark, however due to an increased need
for allogeneic transplants a second center was opened in 2009.
The new center is self-governed with an independent centre ad-
ministration and economy. Upon request the ‘‘old’’ center was
asked to assist in development and training of a data manager
and SCT-team. However, the new center could make indepen-
dent decisions regarding choise of regestries and organization
of work procedures.
Purpose: To describe and discuss the challenges involved in devel-
opmet and training of a data manager (and SCT-team) at a new self-
govening allogeneic transplant center.
Results: The training program for data collection included train-
ing of the following persons from the new center on the following
issues:
A ½ day training of a physician and head nurse: Overall introduc-
tion to data structure and data flow to registries such as the EBMT,
CIBMTR and donor centers including the type of information
needed to be present in the patients’ medical records in order to com-
plete these requirements. Estimated time consumption to complete
the data requirements.
A ½ day of training of a transplant coordinatior: Introduc-
tion to the data manager function, and informaton needed in
the patients’ medical records in order to fulfill the data re-
quirements.
A 2 day training of a data manager: Overall introduction to the
data structure and data flow, the EBMT, CIBMTR and donor reg-
istries and collaboration partners. Further, detailed infomration on
how to organize a patient numbering system, the work load and
keeping track of patients. Introduction on how to fill out different
types of patient reports and how to tab patient information in two
different data base systems. Introduction of the GvHD grading sys-
tems, transplant complications (VOD, TAM etc.), causes of death,
definition, and of difficult questions in the forms. Additionally, the
data manager was provided with guidelines, definitions, instructions,
tools and tips to help ease the work.
Conclusion: For new data managers the medical knowledge re-
quired to complete the forms to the different registries can
seem comprehensive. Training a data manager in a new center
faces the challenges of how the new center wishes to organize
their level of data gathering and reporting and challenges the
‘‘old’’ centers way of organizing the workflow. Cooperation be-
tween different transplant centers on data reporting is beneficial
to both centers.
